SCHEMBL2247759

SCHEMBL2247759

CC(=O)Nc1ccc(-c2nc3ccc(Cl)cc3o2)cc1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 6/20 0.81
CASP3 P42574 6/20 0.81
NPC1 O15118 5/20 0.81
SENP7 Q9BQF6 5/20 0.81
POLB P06746 3/20 0.81
TDP1 Q9NUW8 2/20 0.81
MEN1 O00255 2/20 0.81
KMT2A Q03164 2/20 0.81
SENP8 Q96LD8 3/20 0.69
SENP6 Q9GZR1 3/20 0.69
KDM4E B2RXH2 2/20 0.58
ALDH1A1 P00352 2/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
LMNA P02545 1/20 0.58
THRB P10828 1/20 0.58
MAPT P10636 2/20 0.57
TP53 P04637 2/20 0.56
HPGD P15428 1/20 0.56
HSD17B10 Q99714 1/20 0.56
PARP3 Q9Y6F1 1/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2245090 0.90 CASP3 (1.00) RAB9ACASP3NPC1SENP7POLB
SCHEMBL2249425 0.86 CASP3 (0.83) RAB9ACASP3NPC1SENP7POLB
SCHEMBL7105163 0.86 NPC1 (0.82) RAB9ACASP3NPC1SENP7POLB
SCHEMBL24106598 0.85 CASP3 (0.81) RAB9ACASP3NPC1SENP7POLB
SCHEMBL30965448 0.85 CASP3 (0.81) RAB9ACASP3NPC1SENP7POLB
SCHEMBL2246476 0.85 NPC1 (0.86) RAB9ACASP3NPC1SENP7POLB
SCHEMBL2246641 0.85 NPC1 (0.86) RAB9ACASP3NPC1SENP7POLB
SCHEMBL24454913 0.84 NPC1 (0.72) RAB9ACASP3NPC1SENP7POLB
SCHEMBL23748362 0.84 CASP3 (0.59) RAB9ACASP3NPC1SENP7POLB
SCHEMBL23748365 0.83 CASP3 (0.84) RAB9ACASP3NPC1SENP7POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210387953-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2021-12-16 US claimed
EP-3863755-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS Albert Einstein College of Medicine (US) 2021-08-18 EP claimed
CN-113195084-A Benzoxazoles and related compounds useful as modulators of molecular chaperone-mediated autophagy 阿尔伯爱因斯坦医学院 2021-07-30 CN claimed
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy SUMMIT (OXFORD) LIMITED (GB) 2011-08-11 US claimed
US-12473266-B2 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2025-11-18 US disclosed
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations ALBERT EINSTEIN COLLEGE OF MEDICINE 2024-05-16 US disclosed
CN-113195084-B Benzoxazoles and related compounds useful as modulators of chaperone mediated autophagy 阿尔伯爱因斯坦医学院 2024-04-09 CN disclosed
WO-2023018801-A1 COMPOSITIONS AND METHODS OF ENRICHING HEMATOPOIETIC STEM CELL POPULATIONS AND METHODS OF USE THEREOF ALBERT EINSTEIN COLLEGE OF MEDICINE (US) 2023-02-16 WO disclosed
US-20210387953-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2021-12-16 US disclosed
US-20210387953-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS ALBERT EINSTEIN COLLEGE OF MEDICINE 2021-12-16 US disclosed
CN-113195084-A Benzoxazoles and related compounds useful as modulators of molecular chaperone-mediated autophagy 阿尔伯爱因斯坦医学院 2021-07-30 CN disclosed
EP-3251694-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit (Oxford) Limited (GB) 2017-12-06 EP disclosed
US-20140018320-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2014-01-16 US disclosed
US-20140011782-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2014-01-09 US disclosed
US-8518980-B2 Treatment of Duchenne muscular dystrophy SUMMIT CORPORATION PLC (GB) 2013-08-27 US disclosed
US-8501713-B2 Drug combinations for the treatment of duchenne muscular dystrophy SUMMIT CORPORATION PLC (GB) 2013-08-06 US disclosed
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy SUMMIT (OXFORD) LIMITED (GB) 2011-08-11 US disclosed
US-20090075938-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT (OXFORD) LIMITED (GB) 2009-03-19 US disclosed
EP-1986633-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY Summit Corporation Plc (GB) 2008-11-05 EP disclosed
WO-2007091106-A2 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY SUMMIT CORPORATION PLC (GB) 2007-08-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12473266-B2 Benzoxazole and related compounds useful as chaperone-mediated autophagy modulators CLPX, SQSTM1, ATG7 RAB9A 77/4885CASP3 2371/4885NPC1 807/4885
US-20110195932-A1 Drug Combinations for the Treatment of Duchenne Muscular Dystrophy PYGM, CPT1B, GYS1 RAB9A 3748/4885CASP3 4141/4885NPC1 2477/4885
US-20140011782-A1 DRUG COMBINATIONS FOR THE TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY PYGM, CPT1B, GYS1 RAB9A 3748/4885CASP3 4141/4885NPC1 2477/4885
US-20240156872-A1 Use of Chaperone-Mediated Autophagy Activators For Treating Or Preventing Blood Cancers And Myelodysplastic Syndromes And Enriching Hematopoietic Stem Cell Populations SQSTM1, MCL1, HSPA2 RAB9A 701/4885CASP3 1753/4885NPC1 1454/4885
US-20140018320-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY NR0B1, NR0B2, NR3C1 RAB9A 4325/4885CASP3 2481/4885NPC1 3637/4885
US-20090075938-A1 TREATMENT OF DUCHENNE MUSCULAR DYSTROPHY NR0B1, NR0B2, NR3C1 RAB9A 4325/4885CASP3 2481/4885NPC1 3637/4885
US-20210387953-A1 BENZOXAZOLE AND RELATED COMPOUNDS USEFUL AS CHAPERONE-MEDIATED AUTOPHAGY MODULATORS CLPX, SQSTM1, ATG7 RAB9A 77/4885CASP3 2371/4885NPC1 807/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.